Donanemab and Lecanemab work by clearing the amyloid protein that builds up in the brains of people with Alzheimer’s. Trials suggest they can slow cognitive decline, but not halt the disease. The drugs – set for UK approval in 2024 – mark a turning point in treating a disease that is expected to affect 1.7m Britons by 2040.
“We’re now on the cusp of a first generation of treatments for Alzheimer’s, something that many thought impossible only a decade ago,” said Dr Susan Kohlhaas, executive director of research at Alzheimer’s Research UK. “People should be really encouraged by this news.”
You must log in or register to comment.